Late-Onset Hypogonadism

Reference work entry
First Online:
Part of the Endocrinology book series (ENDOCR)

Abstract

Testosterone (T) levels progressively declines with aging. Symptoms of androgen deficiency are not specific and often overlap with those related to aging. Hence, it is difficult to identify and define late-onset hypogonadism (LOH). The definition of LOH and its clinical significance is a matter of debate as well as the strategies of treating this condition. During the last years, the data produced by the European Male Ageing Study (EMAS) greatly helped in advancing the knowledge on LOH.

In the European general population, LOH has been defined as the presence of low T associated with three sexual symptoms. Thus defined, LOH specifically identifies a condition characterized by the classical features of androgen deficiency. However, according to the EMAS data, LOH is not a homogeneous condition. In fact, a moderate and a severe form, respectively characterized by moderate (8–11 nmol/L) or severe (<8 nmol/L) low T levels, can be identified. Severe LOH is more strongly associated with symptoms and signs of androgen deficiency, thus probably representing a more genuine form of LOH. In European general population, T levels are lower as BMI increases and, accordingly, prevalence of LOH is significantly higher in obese men. In the EMAS study, LOH has been associated also with an increased all-cause and CV mortality and, also in this case, severe LOH exhibits the strongest relationship. The evidence that, similarly to LOH, also sexual symptoms and total T < 8 nmol/L are associated, independently of each other, with an increased mortality complicates the interpretation of the clinical significance of LOH. In fact, at present, it is not clear whether LOH should be considered a pathologic condition, with consequences for well-being and quality of life as well as for general and CV health, or whether it is an epiphenomenon of poor health, representing a marker of frailty, rather than a causing condition. Pending long-term, adequately powered, and designed RCTs, it is unclear whether TRT is useful and beneficial in subjects with LOH and the treatment should be undertaken after comparing possible risks and benefits in each patient and monitoring the onset of side effects, according to the available guidelines.

Keywords

Testosterone Sexual symptoms Late-onset hypogonadism Age Obesity Comorbidities Mortality 
This is a preview of subscription content, log in to check access.

References

  1. Antonio L, Wu FC, O'Neill TW, Pye SR, Ahern TB, Laurent MR, Huhtaniemi IT, Lean ME, Keevil BG, Rastrelli G, Forti G, Bartfai G, Casanueva FF, Kula K, Punab M, Giwercman A, Claessens F, Decallonne B, Vanderschueren D, EMAS Study Groupdagger. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab. 2016;101:2647–57.CrossRefPubMedGoogle Scholar
  2. Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920–6.CrossRefPubMedGoogle Scholar
  3. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241–7.CrossRefPubMedGoogle Scholar
  4. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007–119.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Bancroft J. The endocrinology of sexual arousal. J Endocrinol. 2005;186:411–27.CrossRefPubMedGoogle Scholar
  6. Bandini E, Fisher AD, Corona G, Ricca V, Monami M, Boddi V, Balzi D, Melani C, Forti G, Mannucci E, Maggi M. Severe depressive symptoms and cardiovascular risk in subjects with erectile dysfunction. J Sex Med. 2010;7:3477–86.CrossRefPubMedGoogle Scholar
  7. Banks WA. Leptin transport across the blood-brain barrier: implications for the cause and treatment of obesity. Curr Pharm Des. 2001;7:125–33.CrossRefPubMedGoogle Scholar
  8. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90:678–88.CrossRefPubMedGoogle Scholar
  9. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59.CrossRefPubMedGoogle Scholar
  10. Boddi V, Corona G, Fisher AD, Mannucci E, Ricca V, Sforza A, Forti G, Maggi M. “It takes two to tango”: the relational domain in a cohort of subjects with erectile dysfunction (ED). J Sex Med. 2012;9:3126–36.CrossRefPubMedGoogle Scholar
  11. Boden G, Chen X, Mozzoli M, Ryan I. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab. 1996;81:3419–23.PubMedGoogle Scholar
  12. Brambilla DJ, O’Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol. 2007;67:853–62.CrossRefGoogle Scholar
  13. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56:1278–81.CrossRefPubMedGoogle Scholar
  14. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289:2122–5.CrossRefPubMedGoogle Scholar
  15. Burcelin R, Thorens B, Glauser M, Gaillard RC, Pralong FP. Gonadotropin-releasing hormone secretion from hypothalamic neurons: stimulation by insulin and potentiation by leptin. Endocrinology. 2003;144:4484–91.CrossRefPubMedGoogle Scholar
  16. Camacho EM, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, Tajar A, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Keevil B, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC, EMAS Group. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European male ageing study. Eur J Endocrinol. 2013;168:445–55.CrossRefPubMedGoogle Scholar
  17. Castellano JM, Navarro VM, Fernández- Fernández R, Roa J, Vigo E, Pineda R, Dieguez C, Aguilar E, Pinilla L, Tena-Sempere M. Expression of hypothalamic KiSS-1 system and rescue of defective gonadotropic responses by kisspeptin in streptozotocin-induced diabetic male rats. Diabetes. 2006;55:2602–10.CrossRefPubMedGoogle Scholar
  18. Christensen LW, Clemens LG. Intrahypothalamic implants of testosterone or estradiol and resumption of masculine sexual behavior in long-term castrated male rats. Endocrinology. 1974;95:984–90.CrossRefPubMedGoogle Scholar
  19. Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male. 2008a;11:193–9.CrossRefPubMedGoogle Scholar
  20. Corona G, Fagioli G, Mannucci E, Romeo A, Rossi M, Lotti F, Sforza A, Morittu S, Chiarini V, Casella G, Di Pasquale G, Bandini E, Forti G, Maggi M. Penile doppler ultrasound in patients with erectile dysfunction (ED): role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med. 2008b;5:2623–34.CrossRefPubMedGoogle Scholar
  21. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl. 2009a;32:587–98.CrossRefPubMedGoogle Scholar
  22. Corona G, Ricca V, Bandini E, Mannucci E, Lotti F, Boddi V, Rastrelli G, Sforza A, Faravelli C, Forti G, Maggi M. Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med. 2009b;6:1259–69.CrossRefPubMedGoogle Scholar
  23. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol. 2010;7:46–56.CrossRefPubMedGoogle Scholar
  24. Corona G, Lee DM, Forti G, O’Connor DB, Maggi M, O'Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, Finn JD, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC, EMAS Study Group. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med. 2010a;7:1362–80.CrossRefPubMedGoogle Scholar
  25. Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, de Vita G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med. 2010b;7:1557–64.CrossRefPubMedGoogle Scholar
  26. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, Forti G, Mannucci E, Maggi M. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011a;34:528–40.CrossRefPubMedGoogle Scholar
  27. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J Endocrinol Investig. 2011b;34:557–67.CrossRefGoogle Scholar
  28. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011c;8:272–83.CrossRefPubMedGoogle Scholar
  29. Corona G, Jannini EA, Lotti F, Boddi V, De Vita G, Forti G, Lenzi A, Mannucci E, Maggi M. Premature and delayed ejaculation: two ends of a single continuum influenced by hormonal milieu. Int J Androl. 2011d;34:41–8.CrossRefPubMedGoogle Scholar
  30. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011e;165:687–701.CrossRefPubMedGoogle Scholar
  31. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab. 2011f;25:337–53.CrossRefPubMedGoogle Scholar
  32. Corona G, Rastrelli G, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Body mass index regulates hypogonadism-associated CV risk: results from a cohort of subjects with erectile dysfunction. J Sex Med. 2011g;8:2098–105.CrossRefPubMedGoogle Scholar
  33. Corona G, Rastrelli G, Balercia G, Lotti F, Sforza A, Monami M, Forti G, Mannucci E, Maggi M. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med. 2012a;9:1669–80.CrossRefPubMedGoogle Scholar
  34. Corona G, Jannini EA, Vignozzi L, Rastrelli G, Maggi M. The hormonal control of ejaculation. Nat Rev Urol. 2012b;9:508–19.CrossRefPubMedGoogle Scholar
  35. Corona G, Ricca V, Bandini E, Rastrelli G, Casale H, Jannini EA, Sforza A, Forti G, Mannucci E, Maggi M. SIEDY scale 3, a new instrument to detect psychological component in subjects with erectile dysfunction. J Sex Med. 2012c;9:2017–26.CrossRefPubMedGoogle Scholar
  36. Corona G, Rastrelli G, Ricca V, Jannini EA, Vignozzi L, Monami M, Sforza A, Forti G, Mannucci E, Maggi M. Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction. J Sex Med. 2013;10:1074–89.CrossRefPubMedGoogle Scholar
  37. Corona G, Maseroli E, Rastrelli G, Sforza A, Forti G, Mannucci E, Maggi M. Characteristics of compensated hypogonadism in patients with sexual dysfunction. J Sex Med. 2014a;11:1823–34.CrossRefPubMedGoogle Scholar
  38. Corona G, Rastrelli G, Maseroli E, Fralassi N, Sforza A, Forti G, Mannucci E, Maggi M. Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology. 2014b;2:741–7.CrossRefPubMedGoogle Scholar
  39. Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, Saad F, Mannucci E, Maggi M. Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174:R99–R116.CrossRefPubMedGoogle Scholar
  40. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts male ageing study. Clin Endocrinol. 2006;65:125–31.CrossRefGoogle Scholar
  41. Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, lifestyle, residence, diet and activity. J Clin Endocrinol Metab. 1984;59:955–62.CrossRefPubMedGoogle Scholar
  42. Dhindsa S, Furlanetto R, Vora M, Ghanim H, Chaudhuri A, Dandona P. Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care. 2011;34:1854–9.CrossRefPubMedPubMedCentralGoogle Scholar
  43. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288–99.CrossRefPubMedGoogle Scholar
  44. Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M. Guidelines on male hypogonadism. Arnhem: European Association of Urology; 2015. Available: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Male-Hypogonadism-2015.pdf
  45. Farooqi IS. Leptin and the onset of puberty: insights from rodent and human genetics. Semin Reprod Med. 2002;20:139–44.CrossRefPubMedGoogle Scholar
  46. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589–98.CrossRefPubMedGoogle Scholar
  47. Fernandez-Guasti A, Swaab D, Rodríguez-Manzo G. Sexual behavior reduces hypothalamic androgen receptor immunoreactivity. Psychoneuroendocrinology. 2003;28:501–12.CrossRefPubMedGoogle Scholar
  48. Gamba M, Pralong FP. Control of GnRH neuronal activity by metabolic factors: the role of leptin and insulin. Mol Cell Endocrinol. 2006;254–255:133–9.CrossRefPubMedGoogle Scholar
  49. Garcia-Galiano D, Allen SJ, Elias CF. Role of the adipocyte-derived hormone leptin in reproductive control. Horm Mol Biol Clin Invest. 2014;19:141–9.Google Scholar
  50. Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J, Dzekov C, Sinha-Hikim I, Bhasin S. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab. 2005;90:3838–46.CrossRefPubMedGoogle Scholar
  51. Han TS, Tajar A, O’Neill TW, Jiang M, Bartfai G, Boonen S, Casanueva F, Finn JD, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Pendleton N, Punab M, Silman AJ, Vanderschueren D, Lean ME, Wu FC, EMAS group. Impaired quality of life and sexual function in overweight and obese men: the European Male Ageing Study. Eur J Endocrinol. 2011;164:1003–11.CrossRefPubMedGoogle Scholar
  52. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab. 2001;86:724–31.CrossRefPubMedGoogle Scholar
  53. Hong CY, Park JH, Ahn RS, Im SY, Choi HS, Soh J, Mellon SH, Lee K. Molecular mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine tumor necrosis factor alpha. Mol Cell Biol. 2004;24:2593–604.CrossRefPubMedPubMedCentralGoogle Scholar
  54. Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A, Porst H, Salonia A, Traish AM, Maggi M. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65:99–112.CrossRefPubMedGoogle Scholar
  55. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen JT. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005;90:712–9.CrossRefPubMedGoogle Scholar
  56. Liao C, Reaven E, Azhar S. Age-related decline in the steroidogenic capacity of isolated rat Leydig cells: a defect in cholesterol mobilization and processing. J Steroid Biochem Mol Biol. 1993;46:39–47.CrossRefPubMedGoogle Scholar
  57. Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol. 2008;158:741–7.CrossRefPubMedGoogle Scholar
  58. Lue TF, Brant WO, Shindel A, Bella AJ. Sexual dysfunction in diabetes. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth: MDText.com, Inc.; 2000–2013.Google Scholar
  59. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26:1407–33.CrossRefPubMedGoogle Scholar
  60. Morelli A, Sarchielli E, Comeglio P, Filippi S, Vignozzi L, Marini M, Rastrelli G, Maneschi E, Cellai I, Persani L, Adorini L, Vannelli GB, Maggi M. Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol. 2014;382:107–19.CrossRefPubMedGoogle Scholar
  61. Morley JE, Kaiser FE, Perry 3rd HM, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46:410–3.CrossRefPubMedGoogle Scholar
  62. Mulligan T, Iranmanesh A, Kerzner R, Demers LW, Veldhuis JD. Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig cell) defects in the healthy aging male gonadotropic axis. Eur J Endocrinol. 1999;141:257–66.CrossRefPubMedGoogle Scholar
  63. Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation. 2007;116:2427–34.CrossRefPubMedGoogle Scholar
  64. O’Connor DB, Lee DM, Corona G, Forti G, Tajar A, O’Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, Finn JD, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Labrie F, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC, European Male Ageing Study Group. The relationships between sex hormones and sexual function in middle-aged and older European men. J Clin Endocrinol Metab. 2011;96:E1577–87.CrossRefPubMedGoogle Scholar
  65. Oswal A, Yeo G. Leptin and the control of body weight: a review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity. Obesity (Silver Spring). 2009;18:221–9.CrossRefGoogle Scholar
  66. Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6:1506–33.CrossRefPubMedGoogle Scholar
  67. Pye SR, Huhtaniemi IT, Finn JD, Lee DM, O'Neill TW, Tajar A, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Rutter MK, Vanderschueren D, Wu FC, EMAS Study Group. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab. 2014;99:1357–66.CrossRefPubMedGoogle Scholar
  68. Rastrelli G, Carter EL, Ahern T, Finn JD, Antonio L, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Keevil B, Maggi M, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC, EMAS Study Group. Development of and recovery from secondary hypogonadism in aging men: prospective results from the EMAS. J Clin Endocrinol Metab. 2015;100:3172–82.CrossRefPubMedGoogle Scholar
  69. Rastrelli G, Corona G, Tarocchi M, Mannucci E, Maggi M. How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. J Endocrinol Investig. 2016;39:473–84.CrossRefGoogle Scholar
  70. Rochira V, Zirilli L, Madeo B, Balestrieri A, Granata AR, Carani C. Sex steroids and sexual desire mechanism. J Endocrinol Investig. 2003;26:29–36.CrossRefGoogle Scholar
  71. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab. 2007;92:3568–72.CrossRefPubMedGoogle Scholar
  72. Salvi R, Castillo E, Voirol MJ, Glauser M, Rey JP, Gaillard RC, Vollenweider P, Pralong FP. GnRH-expressing neurons immortalized conditionally are activated by insulin: implication of the MAP kinase pathway. Endocrinology. 2005;147:816–26.CrossRefPubMedGoogle Scholar
  73. Sano T, Kovacs KT, Scheithauer BW, Young Jr WF. Aging and the human pituitary gland. Mayo Clin Proc. 1993;68:971–7.CrossRefPubMedGoogle Scholar
  74. Shi Z, Araujo AB, Martin S, O’Loughlin P, Wittert GA. Longitudinal changes in testosterone over five years in community-dwelling men. J Clin Endocrinol Metab. 2013;98:3289–97.CrossRefPubMedGoogle Scholar
  75. Smith ER, Damassa DA, Davidson JM. Plasma testosterone and sexual behavior following intracerebral implantation of testosterone propionate in the castrated male rat. Horm Behav. 1977;8:77–87.CrossRefPubMedGoogle Scholar
  76. Smith JT, Acohido BV, Clifton DK, Steiner RA. KiSS-1 neurones are direct targets for leptin in the ob/ob mouse. J Neuroendocrinol. 2006;18:298–303.CrossRefPubMedGoogle Scholar
  77. Snyder PJ, Ellenberg SS, Cunningham GR, Matsumoto AM, Bhasin S, Barrett-Connor E, Gill TM, Farrar JT, Cella D, Rosen RC, Resnick SM, Swerdloff RS, Cauley JA, Cifelli D, Fluharty L, Pahor M, Ensrud KE, Lewis CE, Molitch ME, Crandall JP, Wang C, Budoff MJ, Wenger NK, Mohler 3rd ER, Bild DE, Cook NL, Keaveny TM, Kopperdahl DL, Lee D, Schwartz AV, Storer TW, Ershler WB, Roy CN, Raffel LJ, Romashkan S, Hadley E. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clin Trials. 2014;11:362–75.CrossRefPubMedPubMedCentralGoogle Scholar
  78. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler 3rd ER, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS. Testosterone trials investigators: effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611–24.CrossRefPubMedPubMedCentralGoogle Scholar
  79. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85:4500–10.PubMedGoogle Scholar
  80. Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC, EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95:1810–8.CrossRefPubMedGoogle Scholar
  81. Tajar A, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC, EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97:1508–16.CrossRefPubMedGoogle Scholar
  82. Tharp DL, Masseau I, Ivey J, Ganjam VK, Bowles DK. Endogenous testosterone attenuates neointima formation after moderate coronary ballon injury in male swine. Cardiovasc Res. 2009;82:152–60.CrossRefPubMedPubMedCentralGoogle Scholar
  83. Travison TG, Shackelton R, Araujo AB, Hall SA, Williams RE, Clark RV, O’Donnell AB, McKinlay JB. The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc. 2008;56:831–9.CrossRefPubMedPubMedCentralGoogle Scholar
  84. van der Poll T, Romijn JA, Endert E, Sauerwein HP. Effects of tumor necrosis factor on the hypothalamic-pituitary-testicular axis in healthy men. Metabolism. 1993;42:303–7.CrossRefPubMedGoogle Scholar
  85. van Rossum CT, Hoebee B, van Baak MA, Mars M, Saris WH, Seidell JC. Genetic variation in the leptin receptor gene, leptin, and weight gain in young Dutch adults. Obes Res. 2003;11:377–86.CrossRefPubMedGoogle Scholar
  86. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC, International Society of Andrology (ISA), International Society for the Study of Aging Male (ISSAM), European Association of Urology (EAU), European Academy of Andrology (EAA), American Society of Andrology (ASA). Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009;30:1–9.CrossRefPubMedGoogle Scholar
  87. Well D, Yang H, Houseni M, Iruvuri S, Alzeair S, Sansovini M, Wintering N, Alavi A, Torigian DA. Age-related structural and metabolic changes in the pelvic reproductive end organs. Semin Nucl Med. 2007;37:173–84.CrossRefPubMedGoogle Scholar
  88. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93:2737–45.CrossRefPubMedGoogle Scholar
  89. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–35.CrossRefPubMedGoogle Scholar
  90. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab. 2003;88:1730–6.CrossRefPubMedGoogle Scholar
  91. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91:4335–43.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical SciencesUniversity of FlorenceFlorenceItaly
  2. 2.Endocrinology Unit, Department of Experimental and Clinical Biomedical SciencesUniversity of FlorenceFlorenceItaly

Personalised recommendations